PROCESS OF MAKING AND METHOD OF USE OF TETRAHYDROCURCUMINOIDS TO REGULATE PHYSIOLOGICAL AND PATHOLOGICAL EVENTS IN THE SKIN AND MUCOSA CELLS AND CROSS-REGULIN COMPOSITION OF TURMERIC-DERIVED TETRAHYDROCURCUMINOIDS FOR SKIN LIGHTENING AND PROTECTIVE AGAINST UVB RAYS

Abstract: The present invention is directed to a mixture of tetrahydrocurcuminoids which can be used for regulating random intracellular protein crosslinking, optimizing cell electric potential, treating a premalignant state or a malignancy, increasing intracellular transglutaminase activity, and reducing "age spots" due to lipofuscin formation.

Description: Process of Making and Method of Use of Tetrahydrocurcuminoids to Regulate Physiological and Pathological Events in the Skin and Mucosa Cells and Cross-Regulin Composition of Turmeric-Derived Tetrahydrocurcuminoids for Skin Lightening and Protective Against UVB Rays Background of the invention A body cell owes its functioning in large part to its cytoskeleton, the structural framework of the cell. The cytoskeleton is formed by components in the cytoplasm that maintain cell shape, stabilize cell attachments to neighboring cells, and facilitate specialized cell functions like endocytosis, exocytosis and cell motility. The cytoskeleton includes several filamentous structures like microtubules, microfilaments, intermediate filaments, and microtrabecular lattice. Proteins participating in the formation of a cytoskeleton, especially microtubular-associated proteins (MAPS) after being manufactured by the cell, are further adapted to the cytoskeleton function in a process called post-translational modification, or cross- linking. This process of proteins cross-linking is essential to stabilizing the cytoskeleton, the event necessary to maintain cell homeostasis, physiological processes, and cell development and maturation. The post-translational modification of proteins involves several chemical reactions. Protein phosphorylation exemplifies one of the most common mechanisms of post translation modification of cellular proteins. Other examples include methylestrification of proteins, ADP-ribosylation, protein glycosylation, histone acetylation, hypusine formation and transglutaminase-catalyzed reactions. The electric potential of a cell is an aspect of cellular physiology important to the understanding of the mechanism of the invention. The electric potential of a cell is maintained by a complex balance between negatively and positively charged molecules which results in a physiologic resting potential inside the cell of approximately - 70 mV. This value is indicative of the cell's well-being. On the other hand, the inability of a cell to maintain an optimal resting potential occurs in pathological conditions, e.g. physical or chemical assaults, a disease process, and the wear and tear due to aging. Optimal resting potential is conductive to the physiological processes including post-translational protein modification and cross- linking. It also holds true that the intact physiological cross-linking of proteins is indicative of a cell's ability to maintain optimal resting electric potential, Positive effects of cross-linking Cross-linking of proteins, as it has been previously mentioned, is an outcome of the post translational modification of proteins. Some of the most common crosslinks identified in proteins forming cytoskeleton are Neee-(ggg-glutamyl)lysine and N,N-bis(gggglutarnyl)polyamine. The formation of these two types of cross-links is facilitated by the catalytic activity of a group of enzymes known as transglutaminases. One of the well known transglutaminases in the body is coagulation protein Factor XIII. This Factor causes cross-linking of the fibrin, which acts as a stabilizing agent on blood clot formation. This type of modification is an example of a life saving mechanism-based on protein cross-linking, that prevent exsanguination in a cut or a wound. Transglutaminases are responsible for facilitating a physiological process of protein cross-linking, which under normal conditions leads to cell differentiation, thus the cell is able to fulfill its purpose, e.g. mucus secreting cell, phagocytic cell, epithelial and tegumen cell protecting the tissue structure. Transglutaminase activity, or its absence, plays a critical role in the differentiation of cancer cells, especially skin cancer melanoma. Melanoma is a rapidly spreading cancer consisting of undifferentiated skin cells, and the degree of poor cell differentiation correlates well with the suppressed activity of transglutaminase. On the other hand, experimental induction of transglutaminase activity led to promising results in slowing-down or reversing melanoma progression. Examples of transglutaminase inducers are retinoic acid and methylxantines. It appears that the therapeutic potential of retinoids in melanoma is related to their ability to activate intracellular transglutaminases. Detrimental cross-linking Cross-linking of intracellular proteins is, however, not always a positive event. When a random and massive cross-linking is precipitated by an abrupt, non- physiological stimulus, an accelerated aging of the cell occurs. Due to the nature of random crosslinking, which defies the purpose of cell organization and differentiation, this may lead not only to premature cell aging and death, but also can lead to a pathology including malignancy. For example, the UVA-generated free radicals in skin cells can cause premature cross-linking of proteins and liberation of proteolytic enzymes. This latter event leads to the destruction of the cytoskeleton, and the rapid deterioration of cell organization which compromises cell functioning. It is of special interest to mention here the term lipofuscin, nicknamed "the aging pigment" or "liver spots", which occurs in the epidermis and mucous membranes probably as a result of disrupted cellular and systemic metabolism. Lipofuscin has been shown to result from the oxidative degeneration of mitochondria and/or lysosomes in the cells. Lipofuscin is postulated to be a result of a metabolic error which results in hypoanabolism combined with hyperkatabolism. It is postulated here that lipofuscin formation is in part a manifestation of the disrupted process of post-translational protein modification, and that this process intensifies with any systemic disease process, including the aging process. Related art As previously mentioned, transglutaminases are responsible for facilitating the physiological process of protein cross-linking, which under normal conditions leads to cell differentiation, maturation and timely aging. There is considerable evidence that intracellular transglutaminase activity may be inhibited in certain pathology, for example malignancy, e.g. melanoma. It appears that therapeutic potential of transglutaminase inducers like retinoids and methylxantines in melanoma is related to their ability to activate intracellular transglutaminases. This in turn would lead to differentiation of cells, which in clinical practice would lead to a slow down of the disease process due to a decrease in the number of undifferentiated malignant cells. The role of curcuminoids, yellow phenolic compounds derived from turmeric roots (Curcuma longa, fam. Zingiberaceae), as topical antioxidants has been traditionally known in Asia and recently validated in laboratory experiments. Curcuminoids are reported to protect normal human keratinocytes from hypoxanthine/xanthine oxidase injury in in vitro studies, and they can protect the skin against a broad range of physical, chemical and biological factors injuring the skin . Free radicals on the surface of the skin, generated through exposure to ultraviolet radiation, especially the UVB rays, chemicals or other environmental stress factors catalyze aging of the skin. Curcuminoids prevent free radical formation and scavenge free radicals in biological systems. This combined action was previously described as a Bioprotectant mechanism that protects the integrity of the living cell e.g. skin cell. The antioxidant effects of curcuminoids combined with their known inhibitory effects on cyclooxygenase 2 (Cox-2) render them useful as ingredients in anti-aging formulations and in topical formulations designed to maintain general skin health and integrity. Curcuminoids have also been found to inhibit the activity of tyrosinase, an enzyme that participates in melanogenesis, thereby preventing melanin formation with resultant lightening of the skin tone. 2 Tetrahydrocurcuminoids (THC) are color-free compounds derived from curcuminoids, the yellow, parent compounds of THC, in the process of hydrogenation. The process of hydrogenation of curcuminoids can also occur naturally in the gastrointestinal tract. 3 The tetrahydrocurcuminoids' similar biological properties to curcuminoids combined with the lack of yellow color, render them useful in achromatic food and cosmetic applications that currently employ conventional synthetic antioxidants. Like the curcuminoids, THC have also shown significant antioxidant action in a number of in vitro and preclinical studies. 4"9 THC are valued as the ultimate metabolites of the curcuminoids in vivo. Several independent studies validated the significant antioxidant effects of the tetrahydrocurcuminoids and protection of skin against free radicals and UVB rays. Curcumin derivatives including tetrahydrocurcumin and curcuminoids are well recognized in literature as a group of phenolic antioxidants (Majeed et al. Curcuminoid book). Majeed et al., U.S. Patent No. 5,861 ,415 established that the combination of naturally occurring curcuminoids isolated from turmeric root, i.e. curcumin, demethoxy curcumin and bisdemethoxy curcumin produce a broad range of antioxidant protection described as bioprotectant action. Bioprotectant action, characterized by the prevention of free radical formation and intervention in scavenging free radicals, is exerted by tetrahydrocurcumin(oids) (THC) as well as curcumin(oids) (Majeed et a\., Tumeric and the Healing Curcuminoids, Keats Publications 1996 and Majeed et al., Curcuminoids Antioxidant Phytonutrients, NutriScience Publishers 1995). However, tetrahydrocurcumin(oids) show superior free radical scavenging properties, as compared to curcumin or curcuminoids (Majeed et al. Curcuminoid book). Another advantage of tetrahydrocurcuminoids is that they are not as highly colored curcuminoids and thus can be applied topically without significant staining. Recently curcumin but not tetrahydrocurcumin was found to have a preventive effect on cross-linking of collagen in diabetic rats. (Sajithlal GB, Chithra P, Chandrakasan G., Biochem Pharmacol 1998 Dec 15;56(12):1607-14). However, the anti cross-linking effect of curcumin was attained with a very high oral dose of the compound (200 mg/kg body wt.). It was also noted that the preventive effect of curcumin on the advanced cross-linking of collagen was more pronounced than its therapeutic effect. The authors of this study explained that the anti cross-linking mechanism of curcumin is due to quenching the free radicals, which in turn would prevent the accelerated cross-linking of collagen in diabetes. This study supports the use of curcumin to prevent and to some degree treat excessive cross-linking of proteins in conditions characterized by accelerated cross-linking such as diabetes. Description of the invention Applicants have postulated the "cross-regulin" mechanism of THC. This mechanism has been described as both qualitatively and quantitatively different from the prior art. In the experimental work leading to the present application Applicant has evaluated THC in the in vivo model of skin injury by the chemical agent, TPA, and the physical agent, UVB rays. In addition, Applicants have tested the practical results of post-translational modification of proteins with the invention (i e its effect on enzyme tyrosinrase, the enzyme which participates in melanogenesis), Effect of cross-regulin on TPA induced inflammation TPA induces many biochemical and morphological changes in mouse skin, which appear to be associated with inflammation and skin tumor promotion. For example, topical application of TPA to the skin of mice rapidly induced skin inflammation, increased epidermal omithine decarboxylase activity, increased epidermal DNA synthesis, and increased the number of epidermal cell layers. Ornithine decarboxylase (ODC), the first enzyme in polyamine biosynthesis, is highly regulated by many trophic stimuli, and changes in its levels and organization correlate with cytoskeletal changes in human keratinocytes. Therefore, compounds which inhibit TPA and affect ODC synthesis will also affect the organization of the cytoskeleton and related events of post-translatational modification of proteins and crosslinking of proteins in the cytosol. Prior art teaches that chemicals that inhibit TPA-induced biochemical and morphological changes usually inhibit TPA-induced tumor promotion in mouse skin. Applicants have postulated that the crossregulin composition of the invention is an optimal composition for protecting and preserving healthy living cells and for preventing cytoskeletons of the healthy living cells from being damaged by TPA and TPA-like tumor promoters. In an experiment conducted in vivo, the ear skin of Female CF-1 mice was treated with either 20 microliters acetone, TPA in acetone or TPA with Tetrahydrocurcuminoids of the invention [THC1], known Tetrahydrocurcuminoids [THC2] and known pure (synthetic) Tetrahydrocurcumin [THC3]. Five hours later the mice were sacrificed and ear punches were weighted (the higher the weight, score the more severe the inflammation of the treated ear-skin). Based on the weight score of the ear punches, the percent of inflammation inhibition was calculated. Protection against inflammation in decreasing order was furnished by THC1 of the invention, followed by THC2 of the prior art, and finally followed by THC3. The protective effect was dose-dependent concerning THC1 and THC2, while THC3 showed less protection at a dose of 0.36 mg compared to a dose of 0.12 mg. Prior art, as exemplified by the research data, cannot accomplish inhibition of the TPA induced ear edema above 80%. More than 80% inhibition of TPA-induced ear edema is necessary to prevent crosslinking of proteins which could trigger skin cancer. Therefore crossregulin action is not an inherent part of just any composition of THCs, but it is a specific composition that affords inhibition of the TPA mechanism by more than 80%. Another mechanism of the invention is in preserving homeostasis and functioning of cells based on its regulatory, both inhibitory and stimulating, effect on the cross-linking of intracellular proteins. This regulatory mechanism, previously unknown for curcumin and its derivatives, is also unrelated to the well researched and described antioxidant properties of curcumin(oids) and tetrahydrocurcumin(oids). It is a novel way of accomplishing a broad regulatory effect on biological processes. A comparable regulatory effect on cross-linking of proteins in the organism was not described previously with any single compound or with compounded products. In essence the invention differs from other compounds affecting the cross-linking process in that the previously described compounds would stimulate or inhibit intracellular cross-linking, while the invention would act as a cross-linking modifier (CLM) or "crossregulin". These terms are used here for the first time to describe the mechanism of the invention. CLM or crossregulin indicates that a composition of the present invention exerts a positive influence on the post- translational protein modification and cross-linking process in both physiological and pathological conditions alike. The CLM effect of the invention is accomplished by using a specific composition of the product as described in the section "Process of Obtaining THC". The mechanism also occurs with modifications of the THC molecule, for example ether THC, trimethyl ether THC, dimethyl ether THC, benzyl ether THC and potassium, magnesium and copper salts of THC. The mechanism of the invention has been demonstrated in in vivo experimental conditions such as preventing UV sunburn and cross-linking (percent of thymine dimer cells) in the skin cells exposed to UV radiation. The biological properties of the invention were compared with those of curcuminoids, and despite the fact that the present composition is devoid of yellow color it still produces comparable protective effects against UV radiation as that of yellow curcuminoids. This activity appears to be different from the antioxidant effects characteristic of THC and curcuminoids. TPA induces many biochemical and morphological changes in mouse skin, which appear to be associated with skin tumor promotion. For example, topical application of TPA to the skin of mice rapidly induced skin inflammation, increased epidermal ornithine decarboxylase activity, increased epidermal DNA synthesis, and increased the number of epidermal cell layers. Ornithine decarboxylase (ODC), the first enzyme in polyamine biosynthesis, is highly regulated by many trophic stimuli, and changes in its levels and organization correlate with cytoskeletal changes in normal human cells including epidermal keratinocytes [Pomidor MM, Cimildoro R, Lazatin B, Zheng P, Gurr JA, Leigh IM, Janne OA, Tuan RS, Hickok NJ Phosphorylated human keratinocyte ornithine decarboxylase is preferentially associated with insoluble cellular proteins. Mol Biol Cell 1999 Dec;10(12):4299- 310.]. Therefore compounds which will inhibit TPA and affect ODC synthesis will also affect the organization of the cytoskeleton and related events of posttranslational modification of proteins and crosslinking of proteins in the cytosol. The prior art teaches that chemicals that inhibit the TPA-induced biochemical and morphological changes usually inhibit TPA-induced tumor promotion in mouse skin. We have postulated that crossregulin composition of invention is an optimal composition for protecting and preserving healthy live cell and its cytoskeleton from being damaged by TPA and TPA-like tumor promoters. In an experiment carried in vivo the ear skin of Female CF-1 mice was treated with either 20 ul acetone, TPA in acetone or TPA with THcurcuminoids of the invention [THC1], THcurcuminoids of the prior art [ THC2] and pure Thcurcumin [THC3] of the prior art. Five hours later the mice were sacrificed and ear punches were weighted, the higher the weight score the more severe the inflammation of the treated ear-skin. Based on the weight score of the ear punches the percent of inflammation inhibition was calculated. The most protection against inflammation was accomplished with THC of the invention followed by THcurcuminoids of the prior art followed by Thcurcumin of the prior art. The protective effect was dose dependent with THcurcuminoids, while Thcurcumin showed less protection at a dose of 0.36 mg than 0.12 mg. Definition of crossregulin's action: Based on this experimental data, crossregulin's action is based on an anti- inflammatory and cancer preventive mechanism which is limited to any compound that inhibits the inflammatory process by at least 80% in two tested doses (i.e. 0.12 mg and 0.36 mg). Table 1. Effects of THC on TPA-induced ear edema Treatment No. mice Wg/punch %inhibition 1. Acetone 2 6.3 + 0.1 - 2. TPA (1 nmol) 5 14.2 + 0.6 - 3. TPA THC1 0.12 4 7.7 + 0.2 82.3 4. TPA THC1 0.36 m g 4 7.2 + 0.2 88.6 5. TPA THC2 0.12 mg 4 9.6 + 0.5 58.2 6. TPA THC2 0.36 mg 4 8.3 + 0.4 74.7 7. TPA THC3 0.12 mg 4 7.8 + 0.3 81.0 8. TPA THC3 0.36 mg 4 8.1+ 0.3 77.2 Female CF-1 mice were treated topically with 20 ul acetone, TPA (1 nmo!) in acetone or TPA (1 nmol) and test compound in acetone on both ears. Five hours later the mice were sacrificed and ear punches were weighted. Data are expressed as the mean SE THC1 - invention, THC2 - prior art Mimura.et al., US patent 5,266,344 issued Nov. 30, 1993, THC3 - Pure (synthetic) tetrahydrocurcumin. Transglutaminases form a family of proteins that have evolved for specialized functions such as protein crosslinking or posttranslational modification of proteins. In healthy tissues transglutaminases activation and the subsequent protein crosslinking is part of a protective cellular response contributing to tissue homeostasis (e.g. blood clotting, replacement of old cells to give room for a new body cells). Crosslinking has been suggested as one of the mechanisms involved in the aging process. Among the various random or enzyme-mediated crosslinking reactions, transglutaminase induced crosslinking activity has been proposed for its possible involvement in cell proliferation, differentiation and programmed death. In case of a disease state these enzymes have been implicated in a number of pathological conditions including fibrosis, atherosclerosis, neurodegenerative diseases, celiac disease, and neoplastic disease. For example activation of transglutaminases in Alzheimer's disease may be responsible for protein crosslinking leading to deposition of amyloid material in the neural cells. The posttranslational modification or crosslinking of proteins may play an important role in both enhancement and inhibition of the initiation, promotion and spread of cancer in the body. Transglutaminases exhibit true multifunctionality at the molecular level. The crosslinking activity can subseπ e disparate biological phenomena depending on the stage of tumor development. For example, the ras proteins (oncogenes) can be viewed as molecular switches which when crosslinked can initiate human tumors. In certain types of skin moles oncogenes can undergo conversion to melanoma when UVA rays will trigger crosslinking of ras proteins. In that case inhibition of crosslinking will prevent initiation and progression of the malignancy. On the other hand, activation of tissue transglutaminases in poorly differentiated metastatic cancer cell may give rise to crosslinked protein resulting in apoptosis or cancerous cell death. In this example crosslinking of proteins would have a positive impact on the clinical course of the neoplastic disease. In case of cervix carcinomas the findings indicate that specific transglutaminases are upregulated as compared to normal cervix tissue. During rat brain carcinogenesis induced by transplacental administration of N-ethyl-N-nitrosourea, the transglutaminase activity was also increased as compared to the control animals. The invention proposes a practical solution of regulating functions of transglutaminases in both states, health and disease to the advantage treated human or animal organism. The mechanism of crossregulin is unique to a composition of the invention. Prior art, as exemplified by the research data, can not accomplish inhibition of the TPA induced ear edema above the 80%. More than 80% inhibition of TPA induced ear edema is necessary to prevent crosslinking of proteins which could trigger skin cancer. Therefore crossregulin action is not an inherent part of any composition of THCs, but a specific composition that affords inhibition of TPA mechanism by more than 80%. The composition of the invention complies with the definition of crossregulin action. Crossregulin action of the invention in prevention of UVB damage to the skin To further evaluate its crossregulin action, THC1 was tested against UVB- induced damage to the mouse epidermis. Exposure of unprotected skin to UVB causes sunburn, which in principle is an inflammatory reaction to thermal injury to the epidermis. When a dose of UVB radiation, sufficient to induce erythema or thermal injury is administered to the healthy skin, this results in an increased number of epidermal cells with DNA strand breaks (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells), a significant increase in numbers of thymine dimers formed within epidermal cells, and an increase in the number of epidermal cells with wild-type p53 and p21 proteins. These events start within 30 min after UVB exposure. DNA strand breaks increase maximally at 6 hr after UVB exposure, and the number of cells with DNA strand breaks or thymine dimers decrease markedly between 12 and 36 hours. The number of epidermal cells with wild-type p53 and p21 increases at 1 hour after UVB exposure and reaches maximum levels by 8 to 12 hours. The number of p53 and p21 -positive cells decline markedly between 24 and 48 hours after UVB exposure. Topical application of liposomes containing the DNA repairing enzyme, photolyase to UVB-irradiated skin and subsequent exposure to photoreactivating light decreased the number of UVB radiation-induced dimers by 40-45%. The UVB dose administered resulted in the suppression of the intercellular adhesion molecule-1 (ICAM-1 ), a molecule required for immunity and inflammatory events in the epidermis. In addition, in subjects hypersensitive to nickel sulfate, elicitation of the hypersensitivity reaction in irradiated skin areas was prevented. Photolyase-induced dimer repair completely prevented these UVB radiation-induced immunosuppressive effects as well as erythema and sunburn-cell formation. These studies demonstrate that topical application of photolyase is effective in dimer reversal and thereby leads to immunoprotection. The potential UVB-protective effect of THC1 applied to the mouse skin was evaluated against untreated and unexposed skin as well as skin treated with the vehicle and dibenzoylmethane (DBM). DBM is a curcumin-related, beta-diketone analogue which has been reported to exhibit a significant inhibitory effect on 7,12- dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis in Sencar mice. The invention furnishes strong action in preventing sunburn and UVB light-induced formation of thymine dimers (Table 2, 3 and 4). Table 2. Effect of topical application of THC of the invention on UVB light- induced formation of thymine dimers in mouse epidermis Treatment No. mice % thymine dimer cells % protection 1. No UVB 3 0 Acetone + UVB 7 8.9± 0.02 0 THC (10 umol) +UVB 6 7.3+ 0.03 24.7 THC (20 umol)+UVB 6 1.6+ 1.30 82.0 Female SKH-1 mice (8-9 weeks old) were treated topically with 100 ul acetone or the test compound in 100 ul acetone. Five minutes later, the mice were irradiated with a single dose of UVB (30mJ/cm2). The mice were killed one hour later, and skin samples were stored in a 10% formalin-phosphate buffer for thymine dimmers assay. The above experiment illustrates importance of biological strength of THC of the invention to obtain meaningful protection against the UVB damage to the mouse epidermis. The threshold for exerting biological action that translates to protective effect described as crossregulin action is critical to afford a meaningful protection against UVB caused damage to the epidermis. The previously discussed lower than 80% inhibition of TPA induced mouse ear edema would translate to anti- inflammatory but not anti-cancer level of THC activity. Only inherent with the composition of the invention level of biological activity can prevent protein crosslinking (e.g. UVB induced) to the degree that would prevent progression of inflammation into malignancy process. The TPA inhibition experiment shows that even doubling the dose of THCs of the prior art would not provide the above 80% inhibition, whereas THCs of the invention can afford the above 80% inhibition with either of the experimental dose. Further, the single compound THC of the prior art shows less inhibition of TPA with the increase of the experimental dose, that is unlike the composition of the invention which provides dose dependent inhibitory effect. The importance of a minimum biological efficacy of any compound needed to display desired biological effect can not be underestimated. The anti-inflammatory mechanism is different from the anticancer mechanism and both mechanism can be related to a specific level of biological potency. The following describes mechanisms of this invention in detail: 1. It is proposed that in physiologic states characterized by optimal posttranslational protein modification, protein cross-linking, as well as the optimal cell electric potential, THC would not interfere with the above exemplified states of cellular well-being. 2. However, in the states, characterized by poor morphological and functional differentiation of cells, e.g. pre-malignant states or malignancy, THC would contribute to protein post-translational modification and cross-linking and optimization of cell electric potential. This would be accomplished by interaction between phenolic rings and olefinic bonds of THC and NH2 as well as COO groups of the protein amino acids. The resulting bonds would act as an "anchor" that would initiate cross-linking with other proteins. 3. In the states of cell aging and in the states where random cross-linking is precipitated by a thermal injury due to the action of UV rays, for example, the undesired process would be prevented by the invention. THC would prevent undesired cross-linking by attaching to amino and carboxy groups of the protein amino acids. This would result in interference with the random cross- linking, a mechanism comparable to a "buffering" action. This "buffering" action would effectively stop the chain reaction which otherwise would lead to deterioration of cell homeostasis, premature aging and premature cell death. 4. The invention also has a supportive mechanism in preventing random cross-linking of intracellular proteins which is based on the antioxidant properties of THC, specifically on the invention's ability to scavenge free- radicals. It is proposed that due to this antioxidant action it would facilitate disruption of the electric charges of "supercharged" protein molecules, which is one of the reasons why random cross-linking is accelerated. This combined mechanism of crossregulin and antioxidant action is particularly applicable in preventing "age spots" due to lipofuscin formation, and inflammatory conditions such as psoriasis. 5. The source of oxygen moieties in THC for binding to NH2 or COO groups would be from the para hydroxy group no longer in conjugation with the olefinic bond, and from the hydroxy groups of phenolic rings. 6. Unlike the curcumin(oid) compound(s), THC molecule(s) can rotate more freely, thus providing better access to the reactive groups for "anchor" and/or "buffering" reactions. 7. Whereas, as previously mentioned, the invention is relatively inactive in states of cell physiology, its crossregulin mechanism would be gradually expressed proportionate to the degree of stress acting upon the cell. Thus the crossregulin mechanism of THC in the biological system would depend on the kind of injurious action experienced by the biological system. Process of obtaining THC: Tetrahydro curcuminoids of the invention are products of the chemical reduction of curcuminoids, obtained from the rhizomes of Curcuma longa, commonly known as turmeric, or any other suitable plant from the botanical family Zingiberaceae. The prior art teaches that when curcuminoids obtained from Curcuma longa are catalytically reduced and then isolated in the process of crystallization, tetrahydrocurcumin (THC) is recovered without a loss, but with substantial losses of tetrahydrobisdemethoxy curcumin (THBDC) and tetrahydrodemethoxy curcumin (THDC). As a result, the ratio among tetrahydrocurcuminoids is significantly changed as compared to tile original ratio of parent compounds, curcuminoids. The ratio of curcuminoids is preferred, because it correlates with the optimal biological activity of curcuminoids. U.S. Patent No. 5,861 ,415 describes curcuminoids in a specific and optimal ratio as Bioprotectants, providing maximal protective effect of the living cell. The present invention provides a new, more efficient method of recovering THCs. This process prevents the loss of TBDMC and TDMC, and provides a Bioprotectant composition of THCs. THCurcuminoids % content prior art % content invention Tetrahydro curcuminoids 90 75 - 85 Tetrahydro demethoxy curcumin 9 10 - 20 Tetrahydro bisdemethoxy curcumin 1 2 - 4.5 Brief outline of the prior art process for producing THCs Natural curcuminoids (95 %) - 100 gm Acetone - 1 liter Pd-C (catalyst) 5% - 2.5 gm The solution of natural curcuminoids was charged into a hydrogenator. The catalyst was added carefully and the pressure of hydrogen was maintained at about 2 Kg/cm2. This reaction is completed in 3 to 4 hrs. The catalyst is then filtered out and removed. The acetone solution is concentrated under vacuum. The residue is crystallized from toluenes. The tetrahydro compounds are crystallized out as a creamy white powder having a melting point of 92-94°C. Process of the Present invention This process utilizes a novel method of saturation of two olefinic bonds in curcuminoids in the catalytic hydrogen transfer reaction known as a hydride transfer reaction. The following is an example of a hydride transfer method. 1. A 3 liter round bottom flask with a stirrer and a reflux condenser is charged with 1 liter ethyl acetate; 2. The solution is charged with 250 gm of natural curcuminoids in a previously described Bioprotectant composition, i.e. curcumin (C) 70- 80%, Demethoxy curcumin (DMC) 15-20% and Bisdemethoxy curcumin (BDMC 2.5- 6.5% and stirred to uniformity at room temperature; 3. This mixture is charged with 1 liter of triethylamine followed by 12 gm of Palladium carbon and 80 ml of formic acid; 4. The mixture was stirred and subsequently refluxed at 80 deg. Celsius for 12 hours. 5. Periodically formic acid in 5 ml aliquots was charged at 2 hours intervals while a reflux was carried on; 6. TLC was checked to monitor the completion of the reaction, (system: Silica Precoated 0.25 mm thick plates/chloroform : methanol = 9: 1 ); 7. After completion of the reaction, the reaction mixture was cooled to room temperature. It was filtered to remove palladium catalyst and washed with 50 ml of ethyl acetate; 8. Ethyl acetate and triethylamine were distilled off ( 2 liters of distillate was collected); 9. The crude mass was then extracted with toluene (3 x 500 ml); 10. The toluene extract was washed with 200 ml of 5% HCI and 3 x 500 ml of water and dried over sodium sulphate; 11. The solvent was removed under vacuum to get a pale yellow paste approximately 200 gm. 12. The paste was slurred with 200 ml of ether, filtered and dried under vacuum to obtain a pale yellow powder of tetrahydrocurcuminoids, Yield 175 gm (70%). Assay: THC 75 to 85% THDHC 10 to 20% THBDMC 2 to 4.5% In another variation of hydride transfer reaction, curcuminoids were treated with ammonium formate or sodium dihydrogen phosphite (as a catalytic hydrogen transfer reagent) in the presence of Pd/C and acetic acid. The reduction is complete in 20 to 30 minutes at 100 to 110 Celsius degrees. This method yields 50% of tetrahydrocurcuminoids. THC can be administered topically in a suitable vehicle or with an application device, e.g. a transdermal patch, in a concentration ranging from 0.025% to 5%; in the form of subcutaneous injections or a transdermal patch in a concentration ranging from 0.025% to 5%; or in orally administered dosage form in a concentration ranging from 5 mg to 500 mg per dose or 0.083 - 8.3 mg/kg of body weight. THC is suitable for human and animal use. Other routes of administration include but are not limited to: aerosol or other device for delivery to the lungs, nasal spray, intravenous, intramuscular, intraperitoneal, intrathecal, vaginal, and rectal. Excipients which can be used as a vehicle for the delivery of the phage will be apparent to those skilled in the art. Compositions of tetrahydrocurcuminoids for topical administration should be essentially colorless. The term "essentially colorless" is intended to mean that the composition contains no color or such a small amount of color that the composition does not stain the skin upon topical administration. The term "color removed curcumin" refers to the tetrahydrocurcuminoid mixture according to the present invention. THC molecule acting as an "anchor" for amino acids of proteins, to initiate protein cross-links. This mechanism would contribute to the physiological cross-links. Legend: : amino acid/protein THC molecule acting as a buffer in preventing random cross-links in UN precipitated cross-links. This mechanism would contribute to the prevention of pathological cross-links. THC Legend: amino acid/protein INTRODUCTION The study was designed to determine the acute oral toxicity of Colour Removed Curcumin to Sprague Dawley rats. The guidelines followed were as prescribed by the Gaitonde Committee Guidelines, CT-B, New Delhi. PROJECT NO. 4952 MATERIALS AND METHODS TEST SUBSTANCE: Sponsor Sami Chemicals and Extracts Ltd., Bangalore. Label on Sample Colour Removed Curcumin Batch No.- CRC/65 A R No. - BL8C 0445 Description Creamy white crystalline powder Identification LR Spectrum: Complies Solubility Soluble in methanol Purity by HPLC 99.0% PROJECT NO. 4952 SUMMARY The study now reported was designed to determine the acute oral toxicity of Colour Removed Curcumin to Sprague Dawley rats. The test substance suspended in corn oil was administered by oral route to rats. The rats were observed for 14 days after treatment for the product related symptoms. The test substance caused salivation in all animals and polyurea in two animals with onset at 2 hours after the treatment. All animals survived through the study period of 14 days and were free of intoxicating signs 24 hours after the treatment. The LD 50 value of Colour Removed Curcumin in rats by oral route was found to be greater than 5000 mg/kg. TEST SYSTEM Species : Rat Strain : Sprague Dawley Source : I.I.T. Animal house Sex : Male and Female Age ; 6 to 8 weeks Weight range 120.5 to 141.9 gms No. of animals per dose 5 per sex Randomization Randomly selected in groups of five of like sex at the time of initiating the study. Acclimation Not done as the animals were bred and reared in the same Institute, Identification of animals By cage number and individual marking on fur. Diet Pelleted feed supplied by Nav Maharashtra Chskan Oil Mills Ltd., Pune. Water Aquaguard pure water in glass bottles ad libitum. Management The rats were housed 5 each, of the same sex in polypropylene cages provided with bedding of husk. The temperature was maintained between 20 & 24 °C and relative humidity between 50 and 60%; 12 hours each of dark and light cycle was maintained. Route Oral gavage Vehicle used Corn oil Dose volume 10 ml/kg EXPERIMENTAL PROCEDURE The test substance, suspended in com oil was administered once each by oral gavage in rats of both sexes. The rats were starved for 16 hours before and 2 hours after the administration of the test substance. The animals were observed for 14 days after the dosing for the product related toxic symptoms and mortality. Necropsy was carried out in animals died during the observation period. At the end of the observation period the surviving test animals were sacrificed, dissected and examined for gross pathological abnormality, if any. LD 50 in rats Ten rats (5 male and 5 female) was allocated to treatment as follows. RESULTS LD '5cn0 in rats Symptoms: Group 1 - Salivation in all animals and polyurea in two animals were observed with onset at 2 hours after the treatment. All animals survived through the study period of 14 days and were free of intoxicating signs 24 hours after the treatment. Necropsy findings: No significant changes could be seen with naked eye. LD 50 : Greater than 5000 mg/kg. Mortality Table SUMMARY The study was designed to determine the primary skin irritation potential of Colour Removed Curcumin supplied by Sami Chemicals and Extracts Ltd., Bangalore. The test substance in the amount of 500 mg was applied to shorn back skin both intact and abraded site of three rabbits per sex. Each site of application was carefully observed and the reaction evaluated according to Draize's method at 24 and 72 hours. Colour Removed Curcumin did not cause irritation to skin in rabbits. Primary skin irritation score = 0.00. PROJECT NO. 4953 MATERIALS AND METHODS TEST SUBSTANCE: Sponsor Sami Chemicals and Extracts Ltd., Bangalore. Label on Sample Colour Removed Curcumin Batch No.- CRC/65 A R No. - BL8C 0445 Description Creamy white crystalline powder Identification IR Spectrum : Complies Solubility Soluble in methanol Purity by HPLC 99.0% TEST SYSTEM Species : Rabbit Strain New Zealand White Source Serum Institute of India Ltd., Pune. Sex Male and Female Age Healthy adult Weight range 2.00 to 2.40 kg No. of animals per dose 3 per sex Randomization Randomly selected in groups of three of like sex at the time of initiating the study. Acclimation Seven days period to treatment. Identification of animals By cage number and individual marking on ear. Diet Pelleted feed supplied by Nav Maharashtra Chakan Oil Mills Ltd., Pune. Water Aquaguard pure water in glass bottles ad libitum. Management The rabbits were housed individually each, in stainless steel cages provided with stainless steel mesh bottom. The temperature was maintained between 20 & 23 °C and relative humidity between 50 and 60%; 12 hours each of dark and light cycle was maintained. Route Dermal Dose volume 500 mg/site. EXPERIMENTAL PROCEDURE Three rabbits per sex were used for this study. The hair on both the sides were removed by electric clippers one day before the treatment. The test substance in the amount of 500 mg was applied to the intact and abraded skin sites of each test animal. Care was taken to note that the abrasions penetrate the Stratum comeum but not the dermis. A gauze patch was secured over each treated area by means of adhesive tape. The animals were housed singly with plastic collar around their necks for 24 hours, in order to avoid the ingestion of test substance, The patch and unabsorbed test substance was removed after 24 hours. Each site of application was carefully observed and reaction evaluated according to Draize's method at 24 and 72 hours. Draize Evaluation of Skin Reactions - Grading of skin reaction 1. Erythema and Eschar Formation No erythema 0 Very slight erythema (barely perceptible) 1 Well defined erythema , 2 Moderate to severe erythema 3 Severe erythema (beet redness) to slight eschar formation (injuries in depth) 4 Total maximum possible erythema score: 4 2. Edema Formation No edema 0 Very slight edema (barely perceptible) 1 Slight edema (edges of area well defined by definite raising) . , . . 2 Moderate edema (raised approximately 1 mm) 3 Severe edema (raised more than 1 mm and extending beyond area of exposure 4 Total maximum possible edema score: 4 RESULTS Summary of individual dermal irritation score following application of Colour Removed Curcumin on rabbits. Primary skin irritation score 0.00 / 4 = 0.00 PROJECT NO. 4953 CONCLUSION It is concluded based on the present study that of the test substance Colour Removed Curcumin supplied by Sami Chemicals and Extracts Ltd., Bangalore did not cause irritation to skin in rabbits. Primary skin irritation score : 0.00. Scavenging effect (%) of curcumin and its derivatives on 1, 1 -diphenyl-2- picrylhydrazyl radical. Compound concentration (μg/ml) 32.8 16.4 8.2 curcuminoids sample 1 88.09 ±0.4 83.04+1.5 51.20 + 0.9 curcuminoids sample2 88.71 ±0.4 81.51 ±0.1 53.60 + 1.6 tetrahydrocurcumin 88.17 ±0.9 83.00 ±0.7 65.76 ±0.9 tetrahydrocurcumin(NTC) 87.39 ±0.4 82.30 ±1.4 68.61 ±0.8 tetrahydrocurcumin(STC) 84.07 ±2.0 77.13 ±0.8 56.53 ±0.7 * NTC: natural; STC: synthetic. Effect of topical application of curcumin and tetrahydrocurcumin on ultraviolet B light-induced formation of thymine dimers in mouse epidermis Treatment Number of Percent of Percent of per group thymine dimer cells protection 1. No UVB 3 0 2. Acetone + UVB 7 8.9 + 0.02 0 3. THC (10 μmol) + UVB 6 7.3 + 0.03 24.7 4. THC (20 μmol) + UVB 6 1.6 + 1.30 82.0 5. Curcumin (10 μmol) + UVB 5 1.6 + 0.01 82.0 6. Curcumin (20 μmol) + UVB 5 1.2 + 1.69 86.5 Female SKH-1 mice (8-9 weeks old) were treated topically with 100 μl acetone, or test compound in 100 μl acetone. Five minutes later, the mice were irradiated ith a single dose of UVB (30 mJ/crn 2 ). The mice were killed one hour later, and the skin samples were stored in a 10% formalin-phosphate buffer for thymine dimers assay. Effect of UVB-induced formation of skin sunburn cells in mouse epidermis Treatment Number of Percent percent of per group of sunburn cells inhibition No UVB 5 0.1 - Acetone + UVB (60 mJ/cm 2 ) 5 3 - DBM + (10 μmoi) 5 1.2 60 DBM + (20 μmol) 5 0.9 70 Tetrahydrocurcumin (10 μmol) + UVB 5 1 ,6 47 Tetrahydrocurcumin (20 μmol) + UVB 5 1.4 53 Female Sencar mice were irradiated with UVB (60 mJ/cm 2 ). The mice were treated topically with 100 μl acetone or inhibitor in 100 μl acetone at 5 min before the UVB irradiation. Eight hours later, the mice were killed and skin samples were removed and kept in 10% formalin phosphate buffer for sunburn cells assay , Table 3. Effect of Topical Application of Tetrahydrocurcumin on UVB light- induced Sunburn Lesions in SKH-1 Mice Treatment No. mice Days after last dose UVB l . )-)UVB 8 2. Acetone (lOOul) 8 ++++ +++ +++ ++ 3. THC1 (lO uMol) 8 + + Female SKH-1 mice (8-9 weeks old; 8 mice per group) were irradiated with UVB (180 mJ/cm2) once a day for 3 days. The mice were treated topically with vehicle or THC 1 in vehicle once a day for 3 days at 10 min before UVB treatment. The 100 ul vehicle or THC1 treatments were continued once a day until the end of the experiment. The area of sunburn lesion (red color) were measured: (-) no sunburn; (+) slight sunburn; (++) sunburn; (+++) strong sunburn; (++++) very strong sunburn lesion. Table 4. Effect of Dibenzoylmethane (DBM) and tetrahydrocurcuminoids (THCl) on UVB-induced Formation of Sunburn Cells and p21 Protein Levels in Epidermis of SKH-1 Mice Treatment Percent Number of Number of % Of sunburn cells positive cells p21 Sunburn cells per 1 cm slide per 1 cm slide 1. -UVB 0.1 1.8+0.37 1 ,0+0.63 0.04 2. Acetone + UVB (60mJ/cm2) 3.0 22.6+2.79 38.0+7.5 1.4 3. DBM (10 uM) + UVB 1.2 13.2+5.35 33,5+7.49 1.2 4. DMB (20 urn) + UVB 0.9 8.6+1.78 60.6+12.9 2.2 5. THC1 (10 uM) + UVB 1.6 17.8+2.27 31 ,5+8,66 1.0 6. THC1 (20 UM) + UVB 1.4 10,6+2.36 29.8+5.12 1.1 Female Sencar mice (5 mice per group) were treated topically with 100 ul acetone or inhibitor in acetone at 5 min before a single dose of UVB (60 mJ/cm2) irradiation. The mice were killed 8 hours after UVB irradiation, and the skin biopsies were evaluated for sunburn cells and p21 protein. THCl has an UVB-protective effect comparable to DMB; however it may differ from DMB in the way it accomplishes that goal, and specifically in how it regulates Ras p21 protein (Ras p21 protein, an enzyme ubiquitous in the body cells, is central in the cell-signaling system). In cancer cells, this enzyme can undergo uncontrolled cross-linking which locks it in a cancer cell growth-promoting state. In view of the fact that UVB epidermal damage is associated with an increase in the number of p21 positive cells the sunburn-protective mechanism of THCl (without increasing the p21 marker) is a favorable finding for the invention. In addition, the invention protects the epidermis against UVB exposure, resulting in significantly less sunburn which lasted one day less compared to the control group treated with vehicle (Table 3). Therefore the mechanism of the invention is unexpected and differs from prior art quantitatively and qualitatively. It is postulated that shortening the time of epidermal damage by the invention is due to stimulation of several defense compounds including photolyase and ICAM-1 , which leads to epidermal DNA repair. It is further postulated that inhibition of tyrosinase, which furnishes a normalizing effect on photolyase, ICAM-1 and p21 protein is unique to the invention's crossregulin mechanism (i.e. post-translation modification of proteins). Crossregulin action of the invention in inhibition of Tyrosinase As described in the patent applications, which have been incorporated herein, the invention modifies the activity of large group of enzymes called transglutaminases. Transglutaminases form a family of proteins that have evolved for specialized functions such as post-translational modification of proteins. In healthy tissues activation of transglutaminases is part of a protective cellular response that contributes to tissue homeostasis (e.g. blood clotting, replacement of old cells to give room for a new body cells). Crosslinking of proteins or its inhibition has been suggested as one of the mechanisms in post-translational modification of proteins. Among the various random or enzyme-mediated, crosslinking reactions, transglutaminase induced crosslinking activity has been proposed for its possible involvement in cell proliferation, differentiation and programmed death. Transglutaminases exhibit true multifunctionality at the molecular level. The crosslinking activity can promote disparate biological phenomena depending on the state of health of the organism. For example, the oncogenes of certain types of skin moles undergo conversion to melanoma when UV rays trigger the crosslinking of ras proteins. In that case, inhibition of crosslinking will prevent initiation and progression of the malignancy. On the other hand, activation of tissue transglutaminases in poorly differentiated melanoma may give rise to crosslinked protein which may result in apoptosis or cancerous cell death. In this example, crosslinking of proteins would have a positive impact on the clinical course of the neoplastic disease. One of the important aspects of the invention is post-translational modification and inhibition of tyrosinase, an enzyme that is essential for synthesis of the skin pigment, melanin. The net effect of the invention is a significant inhibition of tyrosinase and melanin. However, comparison with prior art reveals that THC1 has least inhibitory effect on tyrosinase than either THC2 or THC3 (Table 5). Table 5. Inhibitory concentrations (IC50) of THC on tyrosinase IC50 (mcg/ml) THC1 0.0493 THC2 0.0155 THC3 0.0000492 The assay for tyrosinase activity was based on the method of Sakuma et al (Arch Pharm Res. 1999. 22(4):335-339).11 Epidermal melanin is known as a photoprotective agent which attenuates UV radiation. 12"14 Photoprotective action of melanin results in diminished erythema of skin exposed to UV rays. Melanin may play an important role in the absorption and scattering of UV light, which may be part of the mechanism in preventing skin cancer as well as an integral part of phototherapy in psoriasis. In experimental animals, exposure to UVB radiation produces suppresses normal immune responses. Immune suppression is important in the development of nonmelanoma skin cancer, and it may influence the development and course of infectious skin diseases. It has been postulated that melanin can provide protection against immune suppression by UVB. There is a consensus that high pigment content in skin is photoprotective against skin cancer, but induced pigment, as in tanning, may not be. The results of an in vitro study show that induced pigment is photoprotective and chemoprotective, but it is less effective in protection against mutagenesis by polychromatic UVB + UVA light. The invention proposes a practical and safe solution to regulate functions of tyrosinase activity. Based on in vitro experimental data THC1 has considerable potential in inhibiting the process of melanogenesis, and this effect is explained by post-translational modification of tyrosinase by THC1. The ability of the invention to inhibit melanogenesis is combined with its superior to the prior art ability to prevent the action of mutagenic compounds on skin cells and protect against sunburn. This combined mechanism of crossregulin is unique to a composition of this invention. This mechanism emphasizes the regulatory action of the invention rather than the inhibitory or stimulatory actions. A comparative study of the invention (THC1 ) and prior art (THC2 and THC3) in the inhibition of tyrosinase has been conducted. In summary, the above experiments illustrate the unique, biological strength of THC1 in preventing TPA induced inflammation and carcinogenesis and inhibiting tyrosinase. References 1. Majeed, M. et al. (1995) Curcuminoids: Antioxidant Phytonutrients. Nut science Publishers, New Jersey. 2. Shirota et al. (1994) Tyrosinase inhibitors from crude drugs. Biol Pharm Bull 17(2):266-269 3. Pan, M.H. et al. (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 27(4):486-94. 4. Osawa, T. et al. (1995) Antioxidative activity of the tetrahydrocurcuminoids. Biosci. Biotechnol. Biochem. 59(9): 1609-12. 5. Sugiyama, Y. (1996) Involvement of the beta-diketone moiety in the antioxidative mechanism of Tetrahydrocurcumin. Biochem Pharmacol, 52(4):519-25 Aug 23 6. Nakamura, Y. et al. (1998) Inhibitory effects of curcumin and tetrahydrocurcuminoids on the tumor- promoter-induced reactive oxygen species generation in leukocytes, in vitro and in vivo. . Jpn J Cancer Res, 89(4):361-70 7. Mukhopadhaya, A. et al. (1982). Anti-inflammatory and irritant activities of curcumin analogues in rats, Agents and Action. 12,2287. 8. Rao, T.S.,_et al. (1982) Antiinflammatory activity of curcumin analogues. Ind J. Med.Res., 75' 574-578 9. Bont'e, F. et al. (1997) Protective effects of curcuminoids on epidermal skin cells under free oxygen radical stress. Planta Med. 63(3):265-266. 10. Mimura.et al., US patent 5,266,344 issued Nov. 30, 1993 11. Sakuma et al. (1999 Aug.). Relationship between tyrosinase inhibitory action and oxidation-reduction potential of cosmetic whitening ingredients and phenol derivatives. Arch Pharm Res. 1999. 22(4):335-339). 12. Kollias N, Sayre RM, Zeise L, Chedekel MR. Photoprotection by melanin. J Photochem Photobiol B 1991 May;9(2):135-160 13. Morison WL. Effects of ultraviolet radiation on the immune system in humans. Photochem Photobiol 1989 Oct;50(4):515-524. 14. Li W, Hill HZ. Induced melanin reduces mutations and cell killing in mouse melanoma. Photochem Photobiol 1997 Mar; 65(3):480-485.

Claims: CLAIMS 1. A method for regulating random intracellular protein cross-linking and optimizing cell electric potential in a patient, comprising administering an effective amount of a mixture of tetrahydrocurcuminoids to a patient in need of such regulation. 2. The method according to claim 1 , wherein said random intracellular protein cross-linking is due to exposure to UV rays. 3. The method according to claim 1 , wherein said random intracellular protein cross-linking is due to the presence of a malignancy. 4. The method according to claim 1 , wherein said intracellular protein crosslinking is regulated by bonding said tetrahydrocurcuminoids to amino and carboxy groups of amino acids. 5. A method for treating a premalignant state or a malignancy in a patient comprising administering an effective amount of a mixture of tetrahydrocurcuminoids to a patient suffering from a premalignant state or a malignancy. 6. The method according to claim 5, wherein said malignancy is melanoma. 7. A method for increasing intracellular transglutaminase activity in a cell comprising administering an effective amount of a mixture of tetrahydrocurcuminoids to a cell with decreased intracellular transglutaminase activity. 8. A method for producing tetrahydrocurcuminoids by saturating two olefinic bonds in a mixture of curcuminoids, comprising the steps of mixing ethyl acetate and curcuminoids at room temperature; adding a catalytic hydrogen transfer reagent followed by palladium carbon and an acid; stirring and subsequently refluxing the mixture while periodically adding aliquots of said acid; cooling the resulting mixture to room temperature; filtering the mixture to remove any palladium carbon; washing the mixture in ethyl acetate; distilling off any ethyl acetate; extracting the resulting crude mass with toluene to produce a toluene extract; washing the toluene extract with HCI and water; drying said extract; removing any remaining toluene under vacuum to produce a paste; mixing said paste with ether to produce a slurry, and filtering and drying said slurry under vacuum to obtain tetrahydrocurcuminoids. 9. The method according to claim 8, wherein said curcuminoids comprise 70-80% curcumin, 15-20% demethoxy curcumin, and 2.5-6.5% bisdemethoxy curcumin. 10. The method according to claim 8, wherein said catalytic hydrogen transfer reagent is selected from the group consisting of triethylamine, ammonium formate and sodium dihydrogen phosphite. 11. The method according to claim 8, wherein said acid is selected from the group consisting of formic acid and acetic acid. 12. A method for producing tetrahydrocurcuminoids by saturating two olefinic bonds in a mixture of curcuminoids, comprising the steps of mixing ethyl acetate and curcuminoids at room temperature; adding a catalytic hydrogen transfer reagent followed by palladium carbon and an acid; heating the resulting mixture; cooling the heated mixture to room temperature; filtering the mixture to remove any palladium carbon; and recovering any tetrahydrocurcuminoids. 13. A mixture comprising 75-85% tertahydrocurcumin, 10-20% tetrahydrodemethoxy curcumin, and 2.0-4.5% tetrahydrobisdemethoxy curcumin, wherein said mixture is substantially colorless. 14. The mixture according to claim 13, wherein said mixture is in a form suitable for topical administration. 15. A method for reducing "age spots" due to lipofuscin formation in a patient in need of such treatment, comprising administering an effective amount of a mixture comprising 75-85% tertrahydrocurcumin, 10-20% tetrahydrodemethoxy curcumin, and 2.0-4.5% tetrahydrobisdemethoxy curcumin to said patient. 16. The method according to claim 13, wherein said composition is administered topically. 17. A colorless mixture comprising tertrahydrocurcumin, tetrahydrodemethoxy curcumin, and tetrahydrobisdemethoxy curcumin. 18. The method according to claim 1 , wherein said random, intracellular cross-linking is post-translational modification of a protein. 19. The method according to claim 1 , wherein said random intracellular cross-linking is modified by the THC to provide safe and effective mucosa, serosa or skin protection against physical, chemical and biologic elements. 20. The method according to claim 1 , wherein said random, intracellular cross-linking is modified by the THC to provide safe and effective skin protection against UVA and UVB. 21. The method according to claim 1 , wherein said random intracellular cross-linking is modified by the THC to effectively inhibit tyrosinase without causing side effects resulting from that inhibition. 22. The method according to claim 1 , wherein said random, intracellular cross-linking is modified by the THC to regulate intracellular ras proteins. 23. The method according to claim 1 , wherein said random, intracellular cross-linking is modified by the THC to inhibit protein cross-linking due to the presence of a malignancy. 24. The method according to claim 1 , wherein said tetrahydrocurcuminoids comprise 70-80% tetrahydrocurcumin, 15-20% tetrahydrodemethoxycurcumin, and 2.5-6.5% tetrahydrobisdemethoxy curcumin. 25. A mixture comprising 70-80% tetrahydrocurcumin, 15-20% tetrahydrodemethoxycurcumin, and 2.5-6.5% tetrahydrobisdemethoxycurcumin, wherein said mixture is substantially colorless. 26. The mixture according to claim 1 , wherein said mixture is in a form suitable for topical administration. 27. The mixture according to claim 1 , wherein said mixture is in a form suitable for oral application. 28. The mixture according to claim 1 , wherein said mixture is in a form suitable for parenteral application.

Inventors: BADMAEV VLADIMIR, MAJEED MUHAMMED, BADMAEV, VLADIMIR, MAJEED, MUHAMMED
Applicants: SABINSA CORP, SABINSA CORPORATION
Application year: 2001
Main classification: A61K31
IPC codes: A61K8, A61K31, A61P17, A61P35, A61Q17, A61Q19